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Abstract
Photodynamic therapy is a complex treatment for neoplastic diseases that
uses the light-harvesting properties of a photosensitizer. The treatment depends
on the amount of photosensitizer in the tissue and on the amount of light that
is focused on the targeted area. We use a pharmacokinetic model to represent
a photosensitizer’s movement through the anatomy and design treatments with
a linear program. This technique allows us to investigate how a treatment’s
success varies over time.
Keywords: Optimization, Photodynamic Therapy
a Trinity University Mathematics, San Antonio, Texas, USA. Corresponding author’s
email is aholder@trinity.edu.
1 Introduction
Photodynamic therapy (PDT) is an emerging treatment that destroys undesirable
tissues and is based on the idea that chemical compounds, called photosensitizers,
cause cellular damage when activated by light. While the underlying chemical pro-
cesses of PDT have been studied over the past century [6, 7, 14], the technique only
recently received US approval for clinical treatments of some cancers, like esophageal
and lung cancer. Canada recently approved trials for prostate cancer. The tech-
nique is widely used to treat age-related macular degeneration [3], but because of the
growing potential for PDT to treat cancer [4], our focus is on modeling oncological
treatments.
Photosensitizers exist in a variety of molecular compositions and structures, and
different compositions react to different wavelengths of light [12, 14]. When a photo-
sensitizer is activated by light, an electron is excited from a ground state to a more
reactive state, converting it to a more energetic species. The excited photosensitizer
converts oxygen to singlet oxygen that in turn destroys cellular material. The excited
electron also causes the formation of super oxide that directly destroys cells. Though
the photochemical reaction results in two destructive processes, the formation of sin-
glet oxygen is regarded as the primary source of cell destruction.
A photosensitizer is designed to aid photodynamic therapy and is synthesized so
that it has an affinity for targeted cells [5]. Cancerous cells possess a high content
of low-density lipoprotein (LDL) receptors, and as a result, the photosensitizer is
designed to be lipophilic in character. A photosensitizer is also constructed to be
water soluble so that it easily flows through tissue. Moreover, a photosensitizer should
quickly degrade, as this reduces the threat of a cytotoxic response (an extensive
exposure of tissue to a foreign species that results in cell death) and the possibility
of future destruction from non-clinical light sources.
In the clinical setting, a patient is injected with a photosensitizer, and after the
drug accumulates in tumorous cells, a light source is focused on the cancerous region.
This causes the photochemical reaction to occur where the photosensitizer is present.
After treatment, the patient avoids light exposure for a period that depends on the
rate at which the photosensitizer is eliminated from the body, a process that can take
up to three months. If the patient does not avoid strong light sources, like the sun,
it is possible for unwanted damage to occur.
The tissue destruction caused by PDT depends on the amount of light, photosen-
sitizer, and oxygen in the tissue. Since these amounts vary over time, modeling cell
destruction is complicated. Only a fraction of the photosensitizer is activated, and
an even smaller fraction of these activated molecules form toxic substances. These
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toxic substances accumulate until they surpass a threshold after which cell death oc-
curs. As discussed in [7], the goal of the physician is to destroy as much tumor as
possible while limiting the damage to surrounding tissues. Our goal is to accurately
model a photosensitizer’s flow through the anatomy and then use this model to design
treatments that address a physician’s goals. Blood and tissue concentrations of a Fed-
eral Drug Administration (FDA) approved photosensitizer are measured via standard
pharmacokinetic techniques (pharmacokinetics is the mathematical analysis of drug
absorption, drug distribution, and drug elimination [2]). Once the distribution of the
photosensitizer is understood, an optimization model is designed that answers several
questions related to PDT. Our optimization model shows how a treatment’s success
depends on the photosensitizer’s affinity for cancerous cells and how light should be
focused during treatment.
2 A Pharmacokinetic Model of Photofrin
The photosensitizer we consider is Photofrin, which is the only FDA approved pho-
tosensitizer for cancer treatment. While other photosensitizers are being clinically
tested, accurate pharmacokinetic data is not available for these photosensitizers.
Photofrin is intravenously injected at 2 mg/kg over a period of five minutes, and
it attains a high saturation level from 48 to 72 hours after injection. The 24 hour
period between the 48th and 72nd hour is called the treatment window, and at some
time within this period a physician focuses a 630nm light on the targeted area. After
treatment, a patient is asked to avoid light exposure for six weeks.
We measure Photofrin’s concentration by placing a grid over the anatomy and
calculating the concentration in each rectangular region. Different tissues absorb and
expel substances from the blood at different rates, and hence the concentration of
Photofrin varies from tissue to tissue. We make the simplifying assumption that each
region is comprised of arterial and non-arterial tissue, where the non-arterial tissue is
homogeneous. Our pharmacokinetic model estimates a region’s concentration by first
calculating the arterial concentration and second using this concentration to guage
the amount of Photofrin in the remaining tissue.
The arterial concentration is modeled via a differential equation that describes
how Photofrin accumulates and degrades in blood-plasma. We let CI be the plasma
concentration during injection, k be the rate of elimination, and k0 be the rate of
infusion. The volume of distribution, V , for a particular drug is the volume of fluid
that the drug would occupy if the total amount of drug in the body were at the same
concentration as is present in the plasma. We model CI with the following first order,
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linear differential equation,
dCI
dt
=
k0
V
− kCI ,
whose solution is,
CI =
k0
V k
[1− e−kt].
The plasma concentration after infusion is CA, which exponentially decays. So,
assuming that the infusion ends at time τ , we have that
dCA
dt
= −kCA, t ≥ τ,
from which we conclude that
CA = CI(τ)e
−kt =
k0
V k
[1− e−kτ ]e−k(t−τ), t ≥ τ .
The infusion rate k0 is based on the fact that the drug is injected at 2mg/kg over a
period of 5 minutes. Using an average 70 kg adult, we have that 140 mg of Photofrin
are delivered in 5 minutes, and thus k0 is 1680 mg/h. The mean volume of distribution
for Photofrin is 0.49 L/kg, and in the case of the 70 kg person, V is 34.3 L. The rate
of elimination, k, is calculated by solving,
t 1
2
= ln(2)/k,
where the half-life for Photofrin is t 1
2
= 516 hours. Hence, k = 0.00134 h−1. Using
these pharmacokinetic parameters for Photofrin1 and an infusion time of τ = .083 h
(5 min), we have for t ≥ .083 that the plasma concentration is
CA = 4.08e
−.00134(t−.083).
We convert CA to Molarity by dividing the concentrations by the molar mass of
Photofrin (596798.4 mg/mol), which means we redefine CA to be
CA =
1
596798.4
(4.08e−.00134(t−.083)).
We use the arterial concentration CA to model Photofrin’s concentration within a
region that contains both arterial and non-arterial tissues. We adapt the blood and
1All parameters are FDA approved and are based on clinical data located at http://www.fda.
gov/cder/foi/label/2003/20451s012_photofrin_lbl.pdf
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tissue flow equations in [13], where a two-stage blood flow model sufficiently estimates
tissue concentrations of radioactively labeled water. We let Cp(t) be the Photofrin
concentration at time t in the non-arterial tissue and Cporph(t) be the Photofrin con-
centration in the entire region. We let k1 and k2 be the tracer rate constants that
describe the flow from tissue to blood and from blood to tissue, respectively. Allowing
VA to be the percentage of arterial tissue in a region, we use the following model to
calculate a region’s concentration at time T ,
Cp(T ) = k1
∫ T
0 CA(t)dt− k2
∫ T
0 Cp(t)dt
CPorph(T ) = VACA(T ) + Cp(T ).
}
(1)
We assume that the rates k1 and k2 are the same (k1 = k2 = 1). The time interval
is divided into equal time steps of length ∆t, and we have from [13] that Model (1)
leads to the following approximate Photofrin concentrations,
CPorph(T ) ≈
VACA(T ) + (k1 + VAk2)
∫ T
0
CA(t)dt− k2
[∫ T−∆t
0
CPorph(t)dt + ∆tCPorph(T −∆t)/2
]
1 + k2∆t/2
.
This approximation is exact as ∆t ↓ 0.
3 Photofrin Activation and Tissue Destruction
The goal of this section is to calculate the rate at which tissue is destroyed during
treatment. This rate of destruction depends on the Photofrin concentrations of the
previous section and on the path of the light source, and we begin this section with an
investigation into how light travels through the anatomy. Consider Figure 1, where
a light source is directed at the patient along angle a. We let d(p,a) be the depth of
region p along angle a and δ(p,a) be the distance between the primary ray and region
p. Light attenuates as it passes through the anatomy (see [10]), meaning that it loses
energy due to absorption and scatter. The attenuation is experimentally close to
exponential decay, with region p receiving
∆ = e
−µ1d(p,a)−(µ2δ(p,a)/d
1/2
(p,a)
)
units of light from a single unit of light entering the anatomy along angle a. The
parameters µ1 and µ2 are decide by the type of light and the width of the beam, with
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Figure 1: The depth measurements of a simple light model.
current technology producing a 5 mm cylindrical beam of 630 nm inferred light. We
set µ1 = 0.02 and µ2 = 0.93 so that the light model in Figures 2 and 3 matched the
experimental data in [10].
We have from [10] that a typical cell perishes once the concentration of activated
Photofrin reaches 17 mM. Allowing α(p,a,t) to be the rate at which Photofrin is acti-
vated in region p by a light source focused along angle a at time t, we have that the
activated Photofrin in region p is
α(p,a,t)x(a,t),
where x(a,t) is the length of time (in seconds) that the light is focused along angle a at
time t. The rate at which Photofrin is activated depends on the laser irradiance Ψ, the
extinction coefficient of the photosensitizer ε, and the concentration of photosensitizer
Cporph at time t. Including the off-axis penetration of light, we have that
α(p,a,t) = εΨCPorph(t)∆. (2)
The irradiance of our light source is Ψ = 0.2 J/cm2s, and the extinction coefficient is
ε = 104 L/(mole cm). In order for α(p,a,t) to be in units of Molarity, the equation is
multiplied by the conversion constant λ/(NAhc) mol/J, where λ is the wavelength of
light, NA is Avogadro’s number, h is Planck’s constant, and c is the speed of light.
4 An Optimization Model
In this section we design an optimization model that is based on the rates α(p,a,t).
The goals of this model are to 1) calculate the best time to treat within the stan-
dard 24 hour treatment window, 2) optimally design a treatment, and 3) investigate
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deposition.
how a photosensitizer’s affinity effects a treatment’s success. We point out that our
problem is similar to that of optimally designing radiotherapy treatments, for which a
substantial literature already exists (see [1, 8, 15, 16]). From an optimization perspec-
tive, the problems are nearly identical, and we modify the model in [9] to meet our
needs. However, radiotherapy uses high-energy particle physics to model how ionizing
radiation damages cells, whereas PDT uses biochemical models to understand how
an activated photosensitizer destroys tissue. The physics models estimate how the
anatomy absorbs radiation, and radiotherapy is grounded in the fact that cancerous
tissues are slightly more susceptible to radiation than normal tissues, a treatment
property called therapeutic advantage. In these models, physicians use their experi-
ence to decide the amount of radiation that is likely to kill a cancerous cell but at
the same time spare healthy cells. Unlike PDT, where we know that cell death oc-
curs once the concentration of activated Photofrin surpasses a threshold, the physics
models do not have a value after which we are guaranteed cell death. Whether or not
there is an innate therapeutic advantage for PDT is unknown, and hence a healthy
cell’s survival depends directly on treatment design and the photosensitizer’s affinity
for cancerous cells.
As in the previous section, we let x(a,t) be the time (in seconds) that a light
source is directed along angle a in time period t. Since α(p,a,t) is the rate at which
the concentration of activated Photofrin accumulates in region p, we have that the
concentration of activated Photofrin in region p is
∑
(a,t) α(p,a,t)x(a,t). Notice that
we are assuming an additive accumulation of activated Photofrin, which means that
we are ignoring cell regeneration during treatment. Cell growth and division have
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been investigated in the radiotherapy literature, where it is understood that cellular
repair is negligible compared to the damage observed during treatment. While PDT
and radiotherapy differ at the molecular level, it is reasonable to assume that the
regenerative effects of the cell cycle are minute in both treatments during the relatively
short treatment times (under an hour in both).
We form a dose matrix, A, from the rates α(p,a,t) by allowing the rows of A to
be indexed by p and the columns by (a, t). Allowing x to be the vector of x(a,t)’s,
where the indices correspond to the columns of A, we have that x 7→ Ax is the linear
operator that takes exposure times, x, and maps them to concentrations of activated
Photofrin, Ax. We partition the rows of A in the following way,
A =

 ATAC
AN

 ← Tumor dose points← Critical dose points
← Normal dose points.
With this notation, we have that AT x, ACx, and ANx are the concentrations of
activated Photofrin in the tumorous, critical, and normal tissues, respectively.
One of our goals is to decide exposure times that best treat the patient. We assume
that the patient image is divided into a 64 × 64 grid (so a patient image has 4096
regions). A physician delineates the three types of tissue on this grid, and our task
is to use this information to decide when the photosensitizer is best distributed and
how the treatment should be administered. For each of the hours within the standard
treatment window, we generate a dose matrix that represents the hour in 15 minute
intervals. For example, for the 50th hour we fix time at 50, 50.25, 50.50, 50.75 and
60 hours, and for each of these times we calculate a dose matrix Ai, i = 0, 1, 2, 3, 4.
The dose matrix for the entire hour is A = [A0|A1|A2|A3|A4]. For each hour in the
treatment window we solve the following linear optimization problem,
min ω1e
T ρ + ω2e
T β + ω3e
T γ
s.t. AT x ≥ (0.017 + ε)− ρ
ACx ≤ 0.017 + β
ANx ≤ 0.017 + γ
x, ρ, β, γ ≥ 0
ρ ≤ (0.017 + ε),


(3)
where e is the vector of ones (length is decided by the context of its use). The first
three constraints are elastic, meaning that their right-hand sides adjusts with ρ, β,
and γ. If these variables are zero, we have achieved the destruction of the tumor
and spared other tissues (assuming the 2nd and 3rd inequalities hold strictly, more
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on this below). The objective function attempts to make ρ, β, and γ as small as
possible, where the weights ω1, ω2, and ω3 decide the relative importance of each
tissue type. The parameter ε is used so that ρ need not be zero to guarantee the
destruction of a cancerous region. If ω2 and ω3 are held constant, we have from [9]
that eT ρ∗(ω1) = O(1/ω1), where ρ
∗(ω1) is optimal for ω1. This result shows that for
an appropriately large ω1 we are guaranteed that ρ
∗(ω1) < ε. We use ω1 = 10, ω2 = 1,
and ω3 = 1/10. The value of ε is 10
−3.
The choice of solver is important to a treatment’s success. There are two (com-
peting) perspectives on solving linear optimization problems. The classical simplex
approach is combinatorial in nature and terminates with a basic-optimal solution.
Such solutions guarantee that many constraints hold with equality, which is not de-
sirable as this guarantees that several non-tumorous regions attain the threshold of
0.017M, causing unwanted and often unnecessary damage. Instead of altering the
model, we use an interior-point method that converges to a solution with clinical ad-
vantages. Many interior-point algorithms follow a structure, called the central path,
toward optimality, and this structure terminates in the strict interior of the optimal
face. Unless there is a unique optimal solution, these algorithms return a solution that
is characteristically different than a basic-optimal solution. In particular, interior so-
lutions strictly satisfy as many inequalities as possible. Hence, using a path-following
interior-point algorithm ensures us that we spare as much non-tumorous tissue as
possible.
Our experiments are conducted on the 4cm × 4cm geometries in Figures 4, 5,
and 6. We only consider angles that are orthogonal to the image, and we assume
that the light source can be focused on the patient from any of the 64 regions of an
image’s face (so there are 4·64 = 256 angles). As discussed in Section 2, each region is
assumed to contain arterial and non-arterial tissues. Unfortunately, we do not know
of a technique that estimates the arterial proportion of a region from a patient image,
and we randomly assign arterial concentrations from a uniform distribution.
We solved each example four times, two with Photofrin having no affinity for
cancerous cells and two with Photofrin having an increased affinity for cancer cells.
This separation allows us to investigate how a treatment’s success is affected by higher
absorption rates in cancerous tissues. This is important because new photosensitizers
are designed so that they accrue in cancer cells up to 6 times more than in muscle [11].
Unfortunately, the chemical properties of these new photosensitizers are not available,
and as a surrogate, we use the known properties of Photofrin and assume that it has
a higher affinity for cancerous cells. From [11] we know that the level of increased
accumulation depends on time and peaks near the middle of the treatment window.
For our experiments we consider the situation where Photofrin concentrations in
9
10 20 30 40 50 60
10
20
30
40
50
60
Figure 4: A tumor grow-
ing between three critical
structures.
10 20 30 40 50 60
10
20
30
40
50
60
Figure 5: A tumor grow-
ing around the left side of
a critical structure.
10 20 30 40 50 60
10
20
30
40
50
60
Figure 6: Four cancerous
regions divided by a sen-
sitive structure.
cancerous regions are multiplied by
6−
5
12
|t− 60|, for 48 ≤ t ≤ 72.
Destruction of the entire tumor is not guaranteed by solving model (3) with our
choices of ω1, ω2 and ω3. If ρ and ε are removed, the model ensures that the entire
tumor is destroyed and minimizes the damage to the critical and normal tissues. Since
the primary focus of the treatment is to remove the threat of cancer, we designed
treatments for each example with and without ρ and ε. So, each example was solved
4 times:
• Photofrin without an increased cancer affinity and ρ and ε removed,
• Photofrin without an increased cancer affinity and ρ and ε included,
• Photofrin with an increased cancer affinity and ρ and ε removed, and
• Photofrin with an increased cancer affinity and ρ and ε included.
Figures 7, 8, and 9 show the percent of tissue that is destroyed when there is no
increased Photofrin accumulation in cancer cells. The curves labeled ‘Tumor’ and
‘Critical’ show how the tumor and critical structures are destroyed by a treatment that
is designed with ρ and ε included. The curve labeled ‘Critical with Tumor Destroyed’
indicates the critical structure damage with ρ and ε removed -i.e. when the entire
cancerous region is destroyed. The fact that these curves are nearly flat indicates
(surprisingly) that without heightened Photofrin concentrations in cancerous tissues,
a treatment’s characteristics are nearly invariant over the treatment window. This
10
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does not mean that the decision variables are the same for each hour, but instead
that the treatments adjust as the Photofrin concentrations change so that the same
amount of tissue is destroyed.
The three examples illustrate that a treatment’s success can vary significantly.
From Figure 7 we see that it is possible to destroy 53% of the tumor in Figure 4 while
destroying 24% of the critical structures. However, guaranteeing the destruction of the
entire tumor requires the destruction of 91% of the critical structures. The problem in
Figure 5 fairs better, as Figure 8 shows that 99% of the tumor is destroyed while less
than 62% of the critical structures is destroyed. If we guarantee tumor destruction,
the critical structures lose 70% of their functional mass. The situation in Figure 9 is
significantly worse, and these curves indicate that destroying the tumor is the same
as destroying the critical structures.
Figures 10, 11, and 12 depict what happens if Photofrin has an increased affinity
for cancerous tissues. The tissue destruction varies over the treatment window, and
each example has an improved treatment. This is especially true for the treatments
in Figure 12, where we see that it is possible to destroy 90% of the tumor and only
36% of the critical structures. Compared with Figure 9, we see that for this example
the increased concentrations of Photofrin in the cancerous regions are crucial to a
successful treatment. The statistics in Table 1 are for the hour having the largest
separation in destruction between the tumor and critical structures. We point out that
the graphs in Figures 10, 11, and 12 exhibit irregular behavior in the 23rd and 24th
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Hour Tumor Critical Separation
Prob. 1 69 78.29% 11.26% 67.03%
Prob. 2 50 76.32% 12.27% 64.05%
Prob. 3 52 89.73% 1.8% 87.93%
Table 1: The treatment hour with the largest separation between destruction of the
cancerous and critical regions.
hour of the treatment window. After a lengthy investigation, we found that the system
used by the interior-point algorithm to decide a step direction becomes increasingly ill-
conditioned as time approaches the 24th treatment hour. This behavior was observed
on numerous examples, and appears to be a product of the differential equation that
models Photofrin concentration.
5 Conclusion
Photodynamic therapy has significant potential in the fight against cancer, especially
as chemists improve a photosensitizer’s capability to localize in cancerous cells. Our
goals were to 1) model a photosensitizer’s blood and tissue concentrations, 2) show
that optimization can aid in the design and delivery of treatments, and 3) investi-
gate how increased localization in cancerous cells effects a treatment’s success. As
12
one would expect, magnifying a photosensitizer’s concentration in tumorous tissue
improves the optimal treatment. This change is substantial for the example in Fig-
ure 6, and it is clear that improving a photosensitizer’s affinity for cancerous cells will
dramatically improve PDT’s viability.
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